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Abstract
Background
The study presents estimates for the burden of visceral leishmaniasis (VL) and cutaneous
and mucocutaneous leishmaniasis (CML) in Brazil and its 27 federated units using data
from the Global Burden of Disease Study (GBD) 2016.
Methodology
We report the incidence, years of life lost (YLL), years lived with disability (YLD), and disabil-
ity-adjusted life years (DALY) for leishmaniasis in Brazil from 1990 to 2016. The metrics are
presented as age-standardized rates per 100,000 inhabitants with their respective uncer-
tainty intervals (95%UI) and relative percentages of change.
Principal findings
The age-standardized incidence rate of leishmaniasis decreased 48.5% from 1990 (71.0,
95%UI 24.3–150.7) to 2016 (36.5, 95%UI 24.7–50.9), whereas the age-standardized DALY
increased 83.6% over the studied period from 12.2 (95%UI 7.9–18.8) to 22.4 (95%UI 13.3–
36.2). The age-standardized incidence rate and YLL for VL increased by 52.9% and 108%
from 1990 to 2016, respectively. Considering CML, the age-standardized incidence rate and
YLD decreased by 51% and 31.8% respectively for the same period. For VL, similar profiles
for male and female were observed, with YLL and DALY increasing over time; with males
presenting slightly higher values. The highest YLL rates were among "under 1-year old" chil-
dren, which increased 131.2% from 1990 to 2016. Regarding CML, the highest values of
YLD and DALY were verified among males, and YLD values showed a similar profile, with
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rates increasing with age. The VL burden increased in some states in the Northeast and
Southeast regions and decreased for CML in some Northern states.
Conclusion
The increase of VL burden over the study period might be associated with the difficulties in
controlling the disease spread. Information regarding the weight of VL and CML, including
the death and disability tolls that they cause, highlights the impact of these neglected dis-
eases on public health and the importance of effective prevention and treatment.
Author summary
Leishmaniasis are diseases caused by obligatory intracellular parasites of the genus Leish-
mania and are transmitted to humans through the bite of female sandflies during blood
repast. Untreated visceral leishmaniasis can lead to death, while cutaneous and mucocuta-
neous forms generally do not pose risk of death but can cause disability and permanent
injury, which raises stigma and social prejudice. The Global Burden of Disease Study
(GBD) is a systematic and scientific effort to quantify the health loss caused by infectious
and non-infectious diseases and injury and their risk factors categorized by age, sex, and
geographic distribution at specific periods of time. The present article describes, for the
first time, the burden of leishmaniasis in the 27 Brazilian federated units. The VL burden
increased in some states in the Northeast and Southeast regions and decreased for CML in
some Northern states. Understanding the burden of these diseases and their regional dif-
ferences is of great relevance for the establishment of adequate and region-specific surveil-
lance and control measures. In addition, it can help in the rational use of available
resources and in decision making aimed at reducing the transmission of the parasite and
the burden of this disabling and potentially lethal disease.
Introduction
Leishmaniasis are neglected tropical diseases (NTD) caused by protozoan parasites of the
genus Leishmania [1,2]. The two distinct clinical forms of the disease are the visceral leishman-
iasis (VL) and the tegumentary leishmaniasis, which comprises cutaneous leishmaniasis,
mucocutaneous leishmaniasis, and diffuse cutaneous leishmaniasis [3,4]. The World Health
Organization (WHO) estimates the annual global occurrence of 400,000 new cases of VL and
1 million new cases of cutaneous and mucocutaneous leishmaniasis (CML) [2,5].
In the Americas, VL is present in 12 countries [6], with 96% of the cases being reported in
Brazil (4,200 to 6,300 cases per year) [1] while CML occurs in 20 American countries, being
endemic in 18 of them, albeit with different transmission intensities [6]. In Brazil, CML affects
72,800 to 119,600 people annually [1]. From1990 to 2016, 84,922 cases of VL were confirmed
in Brazil, with the case-fatality rate reaching 7.4% in 2016 [7]. In the same period, 687,780
cases of CML have been reported, albeit with low mortality [8].
Identifying diseases that pose the greatest threat to health and wellbeing helps policy-mak-
ers planning interventions, monitoring processes, and evaluating the impact and effectiveness
of control measures. The burden of a disease reflects the human and economic costs caused
by the disease and, better than morbidity and mortality indicators, reflects the relative impor-
tance of the disease and disability for the entire population [9,10]. Although the burden of
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leishmaniasis in Brazil has been quantified at a national level, disparities are observed among
different regions [11,12], and subnational analyses are still missing.
The Global Burden of Disease (GBD) is a descriptive epidemiologic study that, since 1990,
quantifies and compares the magnitude of health loss due to diseases and injuries and the risk
factors associated with location, gender, age, and time. The GBD study uses the disability-
adjusted life year (DALY), a measure of health loss due to both fatal and non-fatal disease bur-
den, as the main population health metric. DALYs are estimated by summing years lived with
disability (YLDs) and years of life lost (YLLs) due to premature mortality for a given cause
[11,12].
The 2013 GBD estimated a total of 25.17 million DALYs for the 17 NTDs prioritized by the
World Health Organization and other NTDs in that year; of these, 4.24 million were attributed
to VL and 40,000 DALYs were attributed to CML [13]. Despite the availability of the GBD raw
data, detailed regional analyses are still needed as they could help designing more effective
strategies for controlling the diseases.
Although the burden of leishmaniasis in Brazil has been quantified at a national level, clear
disparities are observed among different regions [11,12] and subnational analyses are still
missing. Identifying levels and trends of leishmaniasis’ burden may help health authorities
plan interventions, monitor processes, and evaluate the impact and effectiveness of the
adopted disease control measures [9,10]. Herein we analyzed the burden of VL and CML
using data from the GBD 2016 for Brazil and its 27 federated units. To the best of our knowl-
edge, this is the first nation-wide analysis of VL and CML burden stratified by gender, age
group, and federated units in Brazil, one of the countries most affected by leishmaniasis in the
world.
Methods
Ethical considerations
The protocol for this study was approved by the Research Ethics Committee of the Federal
University of Minas Gerais (Project CAAE 62803316.7.0000.5149).
Study area
The Federative Republic of Brazil is the largest country in Latin American and the fifth largest
in the world in territory by area, with 8,515,759,090 Km2 (equivalent to 47% of the South
American territory). Regarding population size, the country is the sixth largest, with 207.7 mil-
lion inhabitants in 2017 [14].
Brazil is politically and administratively divided into 27 federated units (26 states and the
Federal District) and 5,570 municipalities. The 27 federated units are grouped into five geo-
graphic regions: Central-West, Northeast, North, Southeast, and South [14].
GBD overview and case definition
The GBD is a project developed by the Institute for Health Metrics and Evaluation with the
aim of creating a comprehensive and up-to-date roadmap of the health problems worldwide
[15]. The general methodological approaches used by GBD 2016 to estimate the metrics are
detailed in previous publications [11,12].
The GBD 2016 provides a comprehensive annual assessment of mortality and morbidity
estimates for 333 diseases and injuries and 84 risk factors for 195 countries and territories
from 1990 to 2016 [16, 17]. The GBD 2016 cause list hierarchy is organized in four levels of
causes that are mutually exclusive and collectively exhaustive [16,17]. Leishmaniasis are within
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the level 2 category “NTDs and malaria”, which consists of 20 infectious and parasitic diseases
including malaria, NTDs prioritized by the WHO, and other important neglected diseases
such as yellow fever and Ebola virus disease. Among the parasitic diseases, leishmaniasis are
divided into VL and CML [16,17]. In the GBD 2016, NTD causes were defined and identified
according to the International Classification of Diseases, 9th (ICD-9) and 10th (ICD-10) Revi-
sions. The specific ICD definitions and modeling strategy for the cause of each leishmaniasis
are described in detail elsewhere [16,17].
Data sources and analysis
The present study describes the metrics generated by the GBD 2016 on leishmaniasis (VL and
CML) in Brazil and its 27 federated units according to time, gender, and age. GBD data sources
for Brazil have been described elsewhere [18,19,20]. The GBD mortality data, as well as the
generation for the YLL estimates, in Brazil come from the Brazilian Mortality Information Sys-
tem (Sistema de Informac¸ão sobre Mortalidade—SIM) adjusted by other national and interna-
tional sources. The main sources of morbidity data, such as the estimates for YLD, are the
Information System of Diseases Notification (Sistema de Informac¸ão de Agravos de Notifi-
cac¸ão—SINAN), the Hospital Information System of the Unified Health System (Sistema de
Informac¸ões Hospitalares do Sistema U´nico de Sau´de—SIH/SUS) and the Outpatient Infor-
mation System of the Unified Health System (Sistema de Informac¸ões Ambulatoriais do Sis-
tema U´nico de Sau´de—SIA/SUS). Additional estimates published in scientific literature on the
prevalence of diseases from Brazilian population-based studies and databases from leishmania-
sis control programs were used [18,19,20].
For the GBD, each death is attributed to a single underlying cause—the cause that initiated
the series of events leading to death, in accordance with the ICD principles [16]. In the GBD
2016, data corrections were made for mortality sub-registration and redistribution of garbage
codes for defined causes based on the GBD 2016 redistribution algorithms [16]. Garbage codes
are the assignment of causes of death that could not or should not be classified as the underly-
ing cause of death [16]. GBD 2016 used Cause of Death Ensemble model (CODEm), negative
binomial regression, and natural history models to estimate the number of deaths for NTD
causes by location, age, gender, and year. For CML, the GBD study assumed that mortality was
null over the years and, therefore, the YLD values were the same as for DALY, which was also
described in a previous study [22]. These modeling strategies for estimating fatal VL were
described in detail elsewhere [16].
The modeling strategy for morbidity estimation and validation of the GBD 2016 has been
published elsewhere [17]. The GBD study uses all available data that meet a minimum stan-
dard of acceptable quality for each disease. GBD 2016 used DisMod-MR 2.1, a Bayesian-
regression analytic tool, to synthesize consistent estimates of prevalence and incidence of non-
fatal outcomes by age, gender, year, and location using a wide range of updated and standard-
ized analytical procedures [17].
The methods used by GBD 2016 to estimate the metrics are detailed in previous publica-
tions [11,12]. The leishmaniasis burden were assessed by the following metrics: incidence;
years of life lost due to premature death (YLL); years lived with disability (YLD); and disabil-
ity-adjusted life year (DALY = YLL + YLD). YLL expresses the effect of premature deaths on
the population and results from the multiplication of the number of deaths due to leishmania-
sis in each age group by the standard life expectancy at age group. For GBD 2016, the standard
life expectancy at birth is 86.6 years, based on the lowest observed death rates for each 5-year
age group in populations greater than 5 million people in 2016 [21]. YLD expresses the sum of
Burden of leishmaniasis in Brazil
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the prevalence of sequelae related to leishmaniasis multiplied by a disability weight [11,12].
Disability weight reflects the severity of health loss associated with the respective disease and it
is presented on a scale varying from 0 (perfect health) to 1 (equivalent to death) [21]. The sum
of YLL and YLD yields DALY [11,12]. The estimates are shown as age-standardized rates by
100,000 inhabitants.
We ranked the federated units from the highest to the lowest value of YLL for VL and from
the highest to the lowest value of YLD for CML. Age-standardized rates were calculated using
GBD world population standard. The metrics were presented with their respective 95% uncer-
tainty intervals (95%UIs) and the relative percentages of change.
Results
The main metrics on the burden of leishmaniasis and the percentage variations between 1990
and 2016 in Brazil are presented in Table 1. Noteworthy, the incidence rates of leishmaniasis
decreased 48.5% from 1990 to 2016, whereas the DALY increased 83.6% over the same period;
the increase of DALY was mainly due to the expressive increase of YLL (108%) (Table 1 and
Fig 1A and 1B).
Table 1. Age-standardized rates of incidence and mortality for leishmaniasis per 100,000 inhabitants and relative change regarding years of life lost (YLL), years
lived with disability (YLD), and disability-adjusted life years (DALY), Brazil,1990–2016, GBD Study 2016.
Metrics Rate per 100,000 (95%UI) Relative change (%)
1990 2000 2016 1990 X 2000 2000 X 2016 1990 X 2016
Leishmaniasis
Incidence 71.0
(24.3–150.7)
67.2
(32.4–124.5)
36.5
(24.7–50.9)
-5.3 -45.6 -48.5
YLL 10.0
(6.0–16.3)
19.6
(11.3–32.1)
20.9
(11.7–34.7)
96.0 6.1 108
YLD 2.2
(0.7–5.0)
2.2
(1.0–4.4)
1.5
(0.9–2.3)
0 -31.8 -31.8
DALY 12.2
(7.9–18.8)
21.7
(13.3–34.2)
22.4
(13.3–36.2)
77.8 3.2 83.6
Visceral Leishmaniasis
Incidence 1.7
(1.4–2.1)
2.9
(2.7–3.2)
2.6
(2.5–2.8)
70.5 -10.3 52.9
YLL 10.0
(6.0–16.3)
19.6
(11.3–32.1)
20.9
(11.7–34.7)
96.0 6.1 108
YLD 0.03
(0.02–0.04)
0.05
(0.03–0.07)
0.04
(0.03–0.06)
67.7 -9.6 51.6
DALY 10.0
(6.1–16.4)
19.6
(11.4–32.1)
20.9
(11.8–34.8)
96.0 6.6 109
Cutaneous and Mucocutaneous Leishmaniasis
Incidence 69.3
(22.4–148.9)
64.3
(29.6–121.6)
33.9
(22.0–48.3)
-7.2 -47.2 -51.0
0.0 0.0 0.0 0.0 0.0 0.0
YLL 0.0 0.0 0.0 0.0 0.0 0.0
YLD 2.2
(0.6–4.9)
2.1
(0.9–4.3)
1.5
(0.9–2.3)
-4.5 -31.5 -31.8
DALY 2.2
(0.6–4.9)
2.1
(0.9–4.3)
1.5
(0.9–2.3)
-4.5 -31.5 -31.8
Cutaneous and Mucocutaneous Leishmaniasis mortality was assumed to be zero; 95%UI: 95% uncertainty interval.
https://doi.org/10.1371/journal.pntd.0006697.t001
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The metric increased for VL and decreased for CML over the years. Considering VL, the age-
standardized incidence rate per 100,000 inhabitants and the YLL increased 52.9% and 108%
from 1990 to 2016, respectively. On the other hand, CML showed a 51% decrease in the age-
standardized incidence rate per 100,000 inhabitants and a 31.8% decrease of the YLD (Table 1).
Fig 1. Age-standardized rates of years of life lost (YLL), years lived with disability (YLD), and disability-adjusted life years
(DALY) per 100,000 inhabitants for Visceral Leishmaniasis (VL) (A) and Cutaneous and Mucocutaneous Leishmaniasis
(CML) (B) per 100,000 inhabitants, Brazil, 1990 to 2016, GBD Study 2016. Visceral Leishmaniasis values of YLD are less than
one. Cutaneous and Mucocutaneous Leishmaniasis mortality was assumed to be zero and for this reason YLL values are zero.
https://doi.org/10.1371/journal.pntd.0006697.g001
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When assessing the GBD indicators of VL by gender, we observed similar profiles for both
genders, with low values of YLD, and YLL and DALY increasing over time for males and
females. Males presented slightly higher values for all these metrics in comparison with females
(Fig 2A and 2B). Regarding CML, the highest values of DALY were verified among males (Fig
2C and 2D).
Fig 2. Age-standardized rates of years of life lost (YLL), years lived with disability (YLD), and disability-adjusted life years (DALY) per 100,000 inhabitants for
Visceral Leishmaniasis (VL) and Cutaneous and Mucocutaneous Leishmaniasis (CML) in 1990, 2000, and 2016, by gender. (A) Rates per 100,000 inhabitants for
males with VL. (B) Rates per 100,000 inhabitants for females with VL. (C) Rates per 100,000 inhabitants for males with CML. (D) Rates per 100,000 inhabitants for
females with CML. Visceral Leishmaniasis values of YLD are less than one. Cutaneous and Mucocutaneous Leishmaniasis mortality was assumed to be zero and for
this reason YLL values are zero. GBD Study 2016.
https://doi.org/10.1371/journal.pntd.0006697.g002
Burden of leishmaniasis in Brazil
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Given that the primary contributor for the burden of the DALY corresponds to YLL for VL
and YLD for CML, the analysis by age and federated units were performed using the values of
YLL for VL and YLD for CML. Fig 3 shows the YLL for VL and the YLD for CML by age. The
highest rates of VL were observed among "under 1-year old" children: 144.3 (95%UI 60.6–
Fig 3. Age-standardized rates of years of life lost (YLL) for Visceral Leishmaniasis (VL) (A) and years lived with disability (YLD) for Cutaneous
and Mucocutaneous Leishmaniasis (CML) (B) per 100,000 inhabitants by age group, Brazil in 1990, 2000 and 2016. CML mortality was assumed
to be zero; YLD is low for VL (premature mortality predominates in VL). GBD Study 2016.
https://doi.org/10.1371/journal.pntd.0006697.g003
Burden of leishmaniasis in Brazil
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255.9) in 1990, 333.7 (95%UI 158.1–603.8) in 2000, and 419.5 (95%UI 207.1–770.6) in 2016.
The YLL for VL among children at this age increased by 131.2% between the years 1990 and
2000 and by 25.7% between 2000 and 2016. The second highest YLL for VL corresponded to
“1 to 4 years old” children, while the YLL values in the other age groups were very low in the
years evaluated (Fig 3A). For CML, YLD values showed a similar profile in the years 1990,
2000, and 2016, with disability rate increasing with age. The YLD decreased over the period
for all age groups (Fig 3B).
The estimated values of YLL for VL per 100,000 inhabitants and the ranking of Brazilian
states in the years 1990, 2000, and 2016 are shown in Table 2 and Fig 4A. The state of Mar-
anhão (Northeast Region) had the highest values of YLL in 1990 (41.2; 95%UI 23.6–69.8) and
in 2000 (111.7; 95%UI 61.0–188.9). In 2016, the highest value of this metric was observed in
Table 2. Age-standardized rates of years of life lost (YLL) per 100,000 inhabitants for Visceral Leishmaniasis considering the Brazilian federated units between
1990 and 2016, GBD Study 2016.
Federated units Year
1990 2000 2016
YLL (95%UI) Ranking YLL (95%UI) Ranking YLL (95%UI) Ranking
Maranhão 41.2 (23.6–69.8) 1 111.7 (61.0–188.9) 1 92.9 (49.8–164.2) 2
Tocantins 40.3 (23.2–62.9) 2 108.5 (64.1–175.2) 2 135.7 (77.8–221.5) 1
Piauı´ 33.9 (20.2–53.7) 3 66.5 (37.3–111.4) 4 79.7 (44.5–135.1) 3
Mato Grosso do Sul 21.7 (12.7–33.3) 4 41.3 (23.9–66.3) 7 50.5 (29.0–80.9) 5
Rio Grande do Norte 21.1 (12.2–33.2) 5 67.1 (38.7–111.9) 3 29.2 (14.9–51.9) 9
Para´ 19.6 (12–30.3) 6 26.9 (15.9–44.1) 11 39.3 (21.5–68.3) 6
Ceara´ 19.2 (11.6–31.7) 7 25.9 (14.8–42.5) 12 57.3 (30.3–100.3) 4
Bahia 18.9 (11.0–31.7) 8 33.3 (18.6–55.8) 8 26.3 (13.9–46.3) 10
Sergipe 17.2 (10.0–26.7) 9 44.4 (25–72.8) 6 31.8 (14.8–55.3) 9
Roraima 16.6 (7.0–29.9) 10 27.0 (12.1–44.4) 10 39.0 (16.0–65.9) 7
Pernambuco 14.2 (8.8–22.8) 11 32.0 (17.8–54) 9 15.1 (8.3–26.4) 11
Paraı´ba 12.4 (6.9–19.5) 12 19.9 (10.3–32) 13 13.7 (5.8–24.7) 12
Minas Gerais 10.1 (6.1–16.9) 13 9.5 (5.3–16.1) 15 32.6 (17.2–58.7) 8
Mato Grosso 8.1 (4.1–13.4) 14 8.1 (3.6–13.7) 16 7.1 (2.8–12.7) 15
Goia´s 6.9 (3.7–10.9) 15 9.9 (5–15.9) 14 8.0 (3.6–14.1) 14
Alagoas 6.6 (3.5–11.1) 16 60.8 (35.6–101) 5 13.0 (5.6–23.6) 13
São Paulo 5.8 (3.4–9.5) 17 4.4 (2.4–7.3) 17 5.7 (3.1–9.7) 16
Espı´rito Santo 2.1 (0.9–3.8) 18 1.7 (0.6–3.4) 18 2.9 (0.7–5.8) 18
Distrito Federal 0.8 (0.3–1.4) 19 1.3 (0.5–2.5) 19 3.6 (0.9–7) 17
Parana´ 0.7 (0.3–1.2) 20 0.4 (0.1–0.8) 22 0.9 (0.2–1.9) 19
Rondoˆnia 0.7 (0.3–1.1) 20 0.7 (0.2–1.2) 20 0.7 (0.2–1.4) 21
Rio de Janeiro 0.6 (0.2–1) 21 0.4 (0.1–0.8) 22 0.7 (0.2–1.4) 21
Amapa´ 0.3 (0.2–0.6) 22 0.3 (0.1–0.5) 23 0.8(0.3–1.6) 20
Amazonas 0.3 (0.1–0.5) 22 0.6 (0.3–1.1) 21 0.5 (0.2–0.9) 22
Santa Catarina 0.3 (0.1–0.6) 22 0.4 (0.1–0.7) 22 0.3 (0.1–0.7) 23
Acre 0.0 (0.0–0.0) 23 0.0 (0.0–0.0) 24 0.0 (0.0–0.0) 24
Rio Grande do Sul 0.0 (0.0–0.0) 23 0.0 (0.0–0.0) 24 0.0 (0.0–0.0) 24
YLL: years of life lost; 95%UI: 95% uncertainty interval of;
 The three highest values of YLL according to the ranking of states per year;
 States with increase in YLL values between 1990 to 2000 and 2000 to 2016 comparisons, according to percentage change calculation. Premature mortality
predominates in VL.
https://doi.org/10.1371/journal.pntd.0006697.t002
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the state of Tocantins (North Region) (135.7; 95%UI 77.8–221.5). The YLL increased from
1990 to 2000 and from 2000 to 2016 in the states of Tocantins, Para´ and Roraima (North
Region), Piauı´ and Ceara´ (Northeast Region), and Mato Grosso do Sul (Central-West Region)
(Figs 4A and 5A).
The estimated values of YLD for CML per 100,000 inhabitants and the ranking of Brazilian
states in the years 1990, 2000, and 2016 are presented in Table 3 and Fig 4B. The state of Acre
(North Region) showed the highest rates in the three years evaluated: 37.8 (95%UI 0.0–193.9)
in 1990, 35.2 (95%UI 2.3–126.0) in 2000, and 27.0 (95%UI 8.1–67.0) in 2016. YLD decreased
in most Brazilian states, with the exception of Maranhão (Northeast Region) and Roraima
(North Region) (Figs 4B and 5B).
Discussion
To the best of our knowledge, the present study is the first comprehensive assessment of the
burden of VL and CML in Brazil and its 27 federated units. The main findings were the con-
siderable changes observed in leishmaniasis burden from 1990 to 2016, with an increase of
83.6% in the age-standardized DALY rate. The increase of leishmaniasis DALY rates was
mainly due to VL, which showed growth in all metrics. On the other hand, CML showed a
decrease in all metrics, with a decrease of 31.8% of the DALY in the same period. Noteworthy,
YLL is the major contributor to the DALY for VL due to the high mortality rates observed for
this disease. On the other hand, the cutaneous and mucocutaneous forms usually cause disabil-
ity rather than death and, therefore, have YLD as the main contributor to the DALY values.
These metrics combine information on mortality and morbidity and allow the estimation
of the impact of each disease or injury on the health status of the population, thus constituting
Fig 4. Age-standardized rates of years of life lost (YLL) for Visceral Leishmaniasis (A) and years lived with disability (YLD) for
Cutaneous and Mucocutaneous Leishmaniasis (B) per 100,000 inhabitants in 1990, 2000 and 2016 considering the federated units
of Brazil. GBD Study 2016.
https://doi.org/10.1371/journal.pntd.0006697.g004
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a fundamental tool for the elaboration of policies aimed at reducing the burden of diseases
[23,24]. In the case of NTDs, the burden imposed by the diseases cannot be calculated consid-
ering mortality only, as they usually cause disability rather than leading to death [25,26,27], as
in the case of CML. Although some cases of death for CML have been recorded in the SIM
database over the years, the GBD study assumes zero mortality for this disease [19]. In 2016,
the group of "NTDs and malaria" ranked ninth in the ranking of incidence among communi-
cable, non-communicable diseases, and injuries in Brazil, with an incidence rate of 5,102.6 per
100,000 inhabitants (95%UI 4,228.6–6,181.7). In the same year, the group ranked 18th in the
ranking of DALY, with a rate of 256.9 (95%UI 205.6–325.9) per 100,000 inhabitants. VL con-
tributed with 8.1% (20.9/100,000 inhabitants; 95%UI 11.8–34.8) to the DALY rate, while CML
contributed with 0.5% (1.5/100,000 inhabitants; 95%UI 0.9–2.3) for the DALY of the same
group [28].
In South America, the three countries with the highest DALY values per 100,000 inhabi-
tants for CML in 2016 were: Bolivia (DALY: 60.6; 95%UI 34.7–97.7), Suriname (DALY: 4.8;
95%UI 2.9–7.3), and Peru (DALY: 2.7; 95%UI 1.4–4.7). Brazil is in the fifth position with a
DALY of 1.5 (95%UI 0.9–2.3) [28]. In the American countries, of the 46,082 CML cases
reported in 2015, 4.2% were mucosal/mucocutaneous. This is considered the most severe
CML form as it can lead to clinical complications, disabilities, and mutilations if not diagnosed
and treated early [6].
Regarding VL, the ranking of South American countries in 2016 was as follows: Paraguay is
the first, with a DALY of 28.5 per 100,000 inhabitants (IU95% 16.2–47.7), followed by Brazil
with a DALY of 20.9 (95%UI 11.8–34.87) and Venezuela with a DALY of 0.3 (95%UI 0.1–0.4)
[28].
Fig 5. Percentages of change calculated for years of life lost (YLL) for Visceral Leishmaniasis (A) and years of life lost (YLD) for
Cutaneous and Mucocutaneous Leishmaniasis (B) per 100,000 inhabitants from 1990to 2016 considering Brazil’s federated units.
GBD Study 2016.
https://doi.org/10.1371/journal.pntd.0006697.g005
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The position of Brazil among the highest rates of DALY for VL indicates a disturbing situa-
tion given the severity of this disease. Indeed, YLL has increased 108% between 1990 and 2016.
The treatment for VL provided by the Brazilian Public Health System consists of three drug
options: pentavalent antimonial (which is considered the first choice), amphotericin B deoxy-
cholate, and liposomal amphotericin B [29,30]. The medication must be taken following medi-
cal advice due to its toxicity and common adverse events [29,30,31,32,33]. Although more
specific guidelines for the management of patients suffering from severe VL have been devel-
oped in Brazil [30], the case fatality rate remains around 8%, which is considered high [34,35].
We observed that all metrics for VL increased over the years, with the incidence rate
increasing by 52.9% from1990 to 2016. This may be explained by the geographic changes
in the incidence of VL cases which have been occurring in the country since 1980,
Table 3. Age-standardized rates of years lived with disability (YLD), per 100,000 inhabitants, for Cutaneous and Mucocutaneous Leishmaniasis and relative change
in the Brazilian federated units between 1990 and 2016, GBD Study 2016.
Federated Units Year
1990 2000 2016
YLD (95%UI) Ranking YLD (95%UI) Ranking YLD (95%UI) Ranking
Acre 37.8 (0.0–193.9) 1 35.2 (2.3–126.0) 1 27.0 (8.1–67.0) 1
Amazonas 13.2 (7.2–21.4) 2 11.9 (6.8–18.9) 3 5.8 (0.9–16.2) 7
Amapa´ 11.4 (0–62.8) 3 15.9 (0.1–74.9) 2 14.9 (2.9–37.4) 2
Maranhão 9.1 (0.0–53.3) 4 10.5 (1.2–37.4) 6 12.3 (6.7–20.9) 4
Mato Grosso 9 (0.0–49.4) 5 10.9 (0.1–47.7) 5 6.5 (1.1–17.6) 6
Rondoˆnia 9 (0.0–51.9) 5 10.2 (0.0–46.3) 7 4.9 (0.8–11.8) 8
Roraima 8.9 (0.0–50.6) 6 11.5 (0.0–51.8) 4 13.3 (1.9–35.5) 3
Para´ 8.7(0.0–51.7) 7 10 (0.1–43.9) 8 7.9 (2.9–17.2) 5
Tocantins 6.7(0.0–37.3) 8 6.8 (0.1–29) 9 4.4 (1–10.8) 9
Bahia 4.5 (0.0–23.1) 9 3.3 (0.0–16.3) 10 2.1 (0.3–5.9) 10
Ceara´ 3.5 (0.0–19.9) 10 3.0 (0.0–13.6) 11 0.9 (0.1–2.3) 11
Piauı´ 2.4 (0.0–14.1) 11 1.3 (0.0–5.7) 14 0.6 (0.2–1.3) 13
Goia´s 2.3 (0.0–12.2) 12 1.6 (0.0–7.3) 12 0.6 (0.1–1.6) 13
Alagoas 2.0 (0.0–10.1) 13 1.4 (0.0–6.5) 13 0.2 (0.0–0.7) 16
Mato Grosso do Sul 1.9 (0.0–10.2) 14 1.3 (0.0–5.6) 14 0.7 (0.1–1.9) 12
Pernambuco 1.9 (0.0–10.7) 14 1.4 (0.0–6.2) 13 0.4 (0.1–1.0) 15
Minas Gerais 1.7 (0.0–9.7) 15 1.6 (0.0–7.0) 12 0.6 (0.1–1.6) 13
Parana´ 1.6 (0.0–9.2) 16 1.4 (0.0–6.1) 13 0.5 (0.1–1.3) 14
Espı´rito Santo 1.2 (0.0–6.8) 17 1.0 (0.0–4.2) 15 0.4 (0.1–1.0) 15
Paraı´ba 1.2 (0.0–7.1) 17 0.7 (0.0–3.1) 16 0.2 (0.0–0.7) 16
Distrito Federal 0.7 (0.0–4.0) 18 0.6 (0.0–2.6) 17 0.2 (0.0–0.6) 16
Sergipe 0.7 (0.0–3.7) 18 0.3 (0.0–1.6) 20 0.1 (0.0–0.3) 17
Rio Grande do Norte 0.7 (0.0–4.1) 18 0.4 (0.0–1.9) 19 0.1 (0.0–0.5) 17
Santa Catarina 0.6 (0.0–3.4) 19 0.5 (0.0–2.3) 18 0.1 (0.0–0.2) 17
São Paulo 0.5 (0.0–2.9) 20 0.4 (0.0–1.8) 19 0.6 (0.1–1.6) 17
Rio de Janeiro 0.4 (0.0–2.3) 21 0.3 (0.0–1.4) 20 0.1 (0.0–0.2) 17
Rio Grande do Sul 0.2 (0.0–0.9) 22 0.1 (0.0–0.4) 21 0.0 (0.0–0.1) 18
YLD: years lived with disability; 95%UI: 95% uncertainty interval;
 The three highest values of YLD according to the ranking of states per year;
 States with increase in YLD values between 1990 and 2000 and 2000 to 2016 comparisons, according to percentage change calculation. CML mortality was assumed to
be zero.
https://doi.org/10.1371/journal.pntd.0006697.t003
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characterized by the expansion to large urban centers and areas previously free of the disease
[36,37,38,39,40].
In the assessment of disease burden for VL, we detected the highest YLL values in children
under the age of five, with a higher rate among children under one year of age. In the year
2016 alone, we detected approximately 420 YLLs/100,000 inhabitants in children under 1-year
of age, regardless of the gender. This pattern of YLL in children confirms the premature mor-
tality due to VL previously observed in Brazil [35,41,42].
Mortality is practically non-existent for CML. CML mortality was assumed to be null by
GBD study, however, the incapacity generated by the lesions in 2016 (YLD) corresponded to
an average of one to two YLL per 100,000 inhabitants.
The first-line treatment for CML consists of pentavalent antimony administration for 3–4
weeks and is indicated for the treatment of all forms of tegumentary leishmaniasis. The poten-
tial hepato, cardio, and nephrotoxicity of the drugs currently available, associated with their
exclusive parenteral administration, represents a great challenge in the search for an adequate
and accessible treatment [43,44]. Moreover, the mucous form requires greater care and may
present slower responses and higher chances of relapses [44]. It is important to emphasize that
most of the cases occur in areas of difficult access, particularly in the middle of the forest in the
North region of the country, which makes both the parenteral application of the drug and the
monitoring of its side effects difficult [45].
The burdens for VL and CML were higher among males in comparison with females in
Brazil. The observed findings may indicate that the risk of infection is often related to occupa-
tional and behavioral factors, as job positions predominantly taken by men may propitiate
contact with the vector and females are usually more likely to seek health services [30,44,46].
The increased number of CML cases is also linked to environmental changes, such as defores-
tation, construction of dams, new irrigation schemes, urbanization, and migration of people
from non-endemic to endemic areas [2].
Among the Brazilian states, Maranhão (Northeast region) presented the highest values
of YLL for VL in 1990 and 2000, followed by the state of Tocantins (North region), which
emerged as first in the ranking for this indicator in 2016. In the 1950s, VL was endemic in rural
areas in the Northeast region of the country [47]. Later it advanced to other states, reaching the
periphery of large urban centers in the states of Para´, Tocantins (North region), Mato Grosso
do Sul (Mid-West region), Minas Gerais, and São Paulo (Southeast region) [32,37,38,39,48,49].
Poverty, the presence of migrants in the urban peripheries, and the migratory flow due to
drought in certain regions are pointed as some of the factors that explain the high values of VL
burden indicators observed in the state of Maranhão in the years of the study [50,51]. For the
state of Tocantins, the ecological and epidemiological changes caused by the construction of
the capital city, Palmas, led to the urbanization and spread of the disease over the years [52].
The state of Acre (North region) maintained the highest rates of YLD for CML, followed by
the states of Amapa´, Roraima (North region), and Maranhão (Northeast region). Previous
studies have suggested that the expansion of tegumentary leishmaniasis in Brazil is associated
with migratory movements originating in the Amazon region. Dispersion of the diseases may
have occurred following the return of the population to their regions of origin in the South
and Southeast Brazil [53, 54]. The return occurred in corridors with the population leaving the
North, passing through the Mid-West and finally reaching the South region of the country
[54]. Since then, there has been an increase both in the magnitude and in the geographical
expansion of CML cases, with notifications in all regions of the country [34,43,44,45].
The Pan American Health Organization (PAHO) reinforces that VL and CML are NTDs
that need continuous efforts for prevention, control, and reduction of incidence in the coming
years [55]. Control strategies should include the diagnosis and treatment, integrated vector
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control, and community health education [56]. In 2016, the Member States of the Pan Ameri-
can Health Organization, under the Resolution CD55.R09 of the Directing Council, approved
the regional plan of action for the elimination of neglected infectious diseases and the post-
elimination actions for 2016–2022, and defined specific objectives to strengthen the surveil-
lance and control of leishmaniasis in the Americas [6]. With the same purpose, the Leishmani-
asis Plan of Action for the Americas 2017–2022 was elaborated detailing the goals, indicators,
and lines of action to reduce morbidity and mortality by leishmaniasis in the region [57]. This
was also the purpose of the United Nations when launching the 2030 agenda for sustainable
development with the goal of drastically reducing the epidemics of AIDS, tuberculosis, malaria
and NTDs, among other communicable diseases [58].
The Brazilian Program of Surveillance and Control of Tegumentary Leishmaniasis aims to
reduce morbidity, deformities, and deaths. Therefore, diagnosis and treatment are the main
strategies of the control program. Likewise, the purpose of the Brazilian VL Surveillance and
Control Program (VLSCP) is to reduce the case fatality rate, the degree of morbidity, and the
risk of VL transmission. The strategies to achieve these goals include canine serological analy-
sis and euthanasia of infected dogs, vector chemical control, early diagnosis and treatment of
human cases, and population awareness [30]. Nevertheless, despite being currently imple-
mented in endemic areas of Brazil, the control interventions for VL remain unsuccessful, and
transmission continues, especially in urban areas [59].
The data shown in the present study has limitations with regards to the coverage and quality
of the databases used by the GBD and the inequalities among the Brazilian federated units. In
addition, it must be taken into account that the cutaneous and mucocutaneous forms present
different clinical management. In routine, cutaneous leishmaniasis patients require lower
doses of medication, and usually have a good response to the treatment, which is usually not as
long as the mucocutaneous form of the disease. In the mucocutaneous form, it would be more
prevalent in men, aged over 40 years, with a reduced immune response, and is aggressive, dis-
figuring and relapsing. Therefore, tegumentary leishmaniasis represents three distinct clinical
forms: cutaneous, mucosal and mucocutaneous [8,22,43]. For the next estimates generated in
relation to the tegumentar forms, the GBD study should consider them separately due to the
differentiated spectrum of the disease.
Indeed, some states, and particularly those located in the North and Northeast regions, still
need better coverage and more extensive recording of cases. Nevertheless, the Brazilian health
databases have seen considerable improvements in the last decades. The SINAN covers all pub-
lic and private healthcare systems and their various levels of complexity. Furthermore, the diag-
nosis and treatment of leishmaniasis are available free of charge in the Brazilian Unified Health
System (SUS) [7,8], which has minimized under reporting. Another point to note is that the
mortality for CML is assumed to be null by the GBD [20], when in fact it occurs in small num-
bers in Brazil [8]. From 2007 to 2014, there were 996 deaths due to tegumentar leishmaniasis
in Brazil (annual mean of 124.5 deaths), with a cumulative total lethality of 0.55% (0.09% for
cutaneous leishmaniasis and 0.46 for other causes) [60]. From this deaths, 155 (15.56%) were
due to tegumentar leishmaniasis and 841 (84.44%) were due for other causes [60]. The litera-
ture indicates that this low mortality may be related to adverse effects during the treatment of
the patients [44,61,62]. Therefore, future estimates should take into account the CML mortality
recorded in the country. Nevertheless, the GBD is the most comprehensive and detailed analy-
sis of the burden of leishmaniasis in Brazil and its federated units and represents a major
improvement in the evidence base for one of the most neglected tropical diseases.
Assessment of the burden of leishmaniasis helps to understand the dynamics of the diseases
and their direct impact on the health status of the population. The data presented here will
allow a more accurate interpretation of the published estimates of the burden of leishmaniasis,
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and the observed regional variations reinforce the need to implement policies adapted to the
reality of each region. The regional trends of life years lost due to death and incapacity
(DALY) caused by leishmaniasis should be carefully analyzed with the purpose of adopting
control strategies specific to the realities of the different Brazilian federated units.
Conclusions
In summary, the findings of the present study show that the burden of VL increased and of
CML decreased over the years in Brazil. The metrics estimated by the GBD 2016 allowed for a
better understanding of the burden of VL and CML in the country and its federated units. It
was observed that the highest values of YLL for VL are concentrated in the Northeast and
Southeast regions due to the urbanization process of the disease. The highest values of YLD for
CML in the North region were due to the ecological, social and migratory conditions that
favor the occurrence of these forms of leishmaniasis, in the country. The increase of VL cases
over the years highlights the need for constant evaluation of the measures of prevention and
control of the disease. Furthermore, our analyses provide a contribution to current health poli-
cies and might help to reduce the burden and control the disease in Brazil, thus promoting
improvements to human and animal health.
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